Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. (June 2017) - Fowler, N.; Gopal, A.K.; Schuster, S.J.; Trotman, J.; Hess, G.; Hou, J.; Yacoub, A.; Lill, M.; Martin, P.; Vitolo, U.; Spencer, A.; Radford, J.; et al.